Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review
about
The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug ReviewA Time-Trend Economic Analysis of Cancer Drug Trials.The politicization of oncology drug funding reviews in Canada.Provincial elections and timing of cancer drug funding.The impact and influence of hope and hype in decision-making about health technologies.Evaluating Frameworks That Provide Value Measures for Health Care Interventions.Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).Timeliness of the oncology drug review process for public funding in Canada.Evolution of cancer treatment and evolving challenges.Understanding the reasons for provincial discordance in cancer drug funding-a survey of policymakers
P2860
Q33834292-76767890-B5A1-44AE-895C-F6B7F60625FFQ34305909-B4108155-F9CB-401F-A7BE-736CEE8142C1Q35820527-5BB0512C-F175-4493-88A6-EF1F7A3BA278Q36989052-83F50479-6486-4F80-B2F4-194388CC45C4Q36989062-1BD3EA25-C26B-43AB-A02B-CF36CC8F4BF3Q38541912-CAA79BB2-8F98-4CA0-98D5-972678008ABBQ38942315-12EDAF2E-6793-4E1A-BD1C-EFB171DA0CD8Q42406982-3D9CBDE7-83D7-4DBC-BD5C-FF740EFA633EQ46058119-D19EEB48-870E-4D90-BC55-8540FAA38A7AQ47123934-68758520-D462-4EE6-9FC5-CA9E3B94AA53Q47139584-B28F1012-05D9-4B79-B530-4F3E024DC876Q49628203-0680FB3A-50D2-4839-9177-922DF801DEE7Q58783208-F29091E2-177D-47ED-A45F-C0DC7A8C008E
P2860
Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Informing Canada's cancer drug ...... -Canadian Oncology Drug Review
@ast
Informing Canada's cancer drug ...... -Canadian Oncology Drug Review
@en
type
label
Informing Canada's cancer drug ...... -Canadian Oncology Drug Review
@ast
Informing Canada's cancer drug ...... -Canadian Oncology Drug Review
@en
prefLabel
Informing Canada's cancer drug ...... -Canadian Oncology Drug Review
@ast
Informing Canada's cancer drug ...... -Canadian Oncology Drug Review
@en
P356
P1433
P1476
Informing Canada's cancer drug ...... -Canadian Oncology Drug Review
@en
P2093
M Sabharwal
P2860
P304
P356
10.3747/CO.20.1315
P577
2013-04-01T00:00:00Z